Biosimilars Market Size & Share, by Product Type (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides); Technology (Bioassay Technology, Recombinant DNA Technology, Monoclonal Antibody Technology); Application (Hematology, Oncology, Autoimmune Diseases) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 1376
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Companies Dominating the Biosimilars Landscape

top-features-companies
    • Biocon Limited
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Amgen Inc.
    • Novartis AG
    • Intas Pharmaceuticals Ltd.
    • BioXpress Therapeutics SA
    • Genor Biopharma Co. Ltd
    • Allergan plc (AbbVie Inc.)
    • Coherus BioSciences, Inc.
    • Pfizer Inc.
    • Reliance Life Sciences Private Limited

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Biocon Limited - Abevmy (bBevacizumab) is now available in Canada. It is co-developed by Biocon Biologics (a subsidiary of Biocon Limited) and Viatris and is a biosimilar to Roche’s Avastin (Bevacizumab). Health Canada has approved the drug for four oncology indications.

  • Amgen Inc., - announced the approval of RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab) by the U.S. Food and Drug Administration (FDA). It is used for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 1376
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising burden of various diseases as well as a reduction in direct spending on biologics along with increasing development and commercialization of biosimilars are some of the major factors anticipated to drive the growth of the market.

The market is anticipated to attain a CAGR of 23 % over the forecast period, i.e., 2023-2033.

Stringent regulatory policies for approval of biosimilars along with concerns about manufacturing processes of biosimilar agents are some of the factors estimated to hamper the market growth.

Stringent regulatory policies for approval of biosimilars along with concerns about manufacturing processes of biosimilar agents are some of the factors estimated to hamper the market growth.

The market in Europe garnered the highest market share in 2022 and is projected to provide more business opportunities in the future.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, technology, application, and by region.

The oncology segment garnered the highest market share and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying